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Groundwater arsenic (As) has affected millions of people globally distributed over 20 countries. In parts
of West Bengal (India) and Bangladesh alone, over 100 million people are at risk, but supply of As-free
water is grossly inadequate. Attempts to remove As by using orthodox medicines have mostly been
unsuccessful. A potentized homeopathic remedy, Arsenicum Album-30, was administered to a group
of As affected people and thereafter the As contents in their urine and blood were periodically determ-
ined. The activities of various toxicity marker enzymes and compounds in the blood, namely aspartate
amino transferase, alanine amino transferase, acid phosphatase, alkaline phosphatase, lipid peroxidation
and reduced glutathione, were also periodically monitored up to 3 months. The results are highly encour-
aging and suggest that the drug can alleviate As poisoning in humans.
Keywords: arsenic toxicity – Arsenicum Album-30 – enzyme biomarkers – homeopathy –
human trial – remedy
Introduction
Prolonged exposure to arsenic (As), a toxic metalloid, has
caused various illnesses to millions of people globally distrib-
uted over 20 countries. In Bangladesh and its adjoining part of
West Bengal (India) alone, 100 million people are at risk (1)
of As poisoning because of drinking contaminated ground-
water having concentrations of As ranging 60–560.23 mgl
1,
much exceeding the maximum permissible limits laid down
by both WHO (2) and US Environmental Protection Agency
(3). The attempts made so far by both Governmental and
Non-Governmental organizations to provide As-free drinking
water to the highly affected areas remain grossly inadequate.
Furthermore, As enters the bodies of unsuspecting villagers
not only through drinking water alone but also a substantial
amount enters through food and vegetables grown in contam-
inated land around the village (1). We, therefore, feel that ser-
ious efforts should also be directed to remove As after it
enters the body. However, orthodox medicines (e.g. chelating
agents like Dimercaptosuccinic acid (DMSA), Diethyl-
enetriamine-pentaacetic acid (DTPA) etc., and some antioxid-
ants) have been most unsuccessful (1,4,5). Chronic exposure
generally leads to various ailments and the dysfunction of sev-
eral vital organs like the liver, kidney,lung, etc. (6), more often
when there is an accompanying nutritional/dietary deficiency
(7). Most of the affected people in general complain of muscle
and joint pains and are highly depressed with various gastric
problems and general weakness. Many people look pale
and anemic and seem resigned to fate. In such a scenario, our
efforts are directed to find a remedy that is inexpensive, easy
to administer, effective in low doses and has no toxic effect
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to mobilize Arsenic in rats through microdoses of Arsenicum
Album, and our extensive studies in mice (10–16) suggested
that Arsenicum Album-30 has the potential to alleviate As
toxicity in humans as well. The favorable response to an early
trial (17,18) prompted us to undertake this first human trial, the
initial results of which are reported in this paper.
In this trial, we monitored the changes in As concentrations
in urine and blood and also the activities of several enzymes
and toxicity biomarkers, viz., aspartate amino transferase
(AST), alanine amino transferase (ALT), acid phosphatase
(AcP), alkaline phosphatase (AlkP), lipid peroxidation
(LPO) and reduced glutathione (GSH) after administration
of the ultralow doses of the Arsenicum Album-30. Any
increase in the concentration of As in the urine accompanied/
followed by a decrease in the blood after drug treatment was
viewed as resulting from the removal of As from the body.
Similarly, any increased activity in the favorable biomarkers
and decrease in enzymes indicating toxicity were taken as
evidence of alleviation of As toxicity.
Methods
Subjects
Arsenic Location: As was first detected in 1995 in the tube
wells of the village, Ghetugachhi under Chakdaha Block,
District Nadia, West Bengal. As-free water plant was sub-
sequently installed in November 2002 in this village, after a
huge mortality had been reported due to arsenicosis. From
that time, villagers were warned against drinking water from
any other source (few tube wells in the village were sealed
by the Government) and advised strictly to use water of the
As-free plant for drinking purposes. However, most of them
use other water sources for cooking and other purposes and
occasionally drink contaminated tube well water when they
work in the field. Therefore, even though these villagers are
at risk of As contamination to a lesser degree than before and
have a lower mortality rate, many people still show symptoms
of arsenicosis albeit to a lesser extent.
Group One: When the villagers were initially approached
with the request to act as volunteers in our trial on the efficacy
of a potentized homeopathic drug, Arsenicum Album, most of
them were visibly reluctant, presumably because (i) many of
them simply did not believe in homeopathy; and (ii) some
researchers had earlier taken blood, urine, nail and hair
samples promising to give effective remedies, but never
came back with the results or the promised remedy! After great
persistence, however, a group of 55 people comprising
32 males and 23 females (Group I, Table 1) living in this
village agreed to become subjects of a double-blind placebo-
controlled trial only for analyzing urine As content for a few
days (11 days only). The persons of this group took a dose
of either ‘verum’ (Arsenicum Album-30 soaked globules) or
‘placebo’ (Alcohol-30 soaked globules) twice daily for 10
consecutive days, each dose containing eight small globules
(No. 20) soaked with the medicine/placebo. The information
whether they were taking the placebo or the drug was kept
from them. At the end of the experiment when the codes
were deciphered it was found that 22 and 33 persons received
‘placebo’ and ‘verum’, on a random basis. The urine samples
were taken daily up to 11 days after the first administration
of drug/placebo and analyzed for As content. These data
were critically analyzed and were utilized as controls for
another group of people (Group II), who were persuaded
later to undertake the trial for a longer period and were reques-
ted to give not only urine samples periodically, but also
blood as well, so that not only the relationship of As concentra-
tion in urine and blood could be fairly extrapolated but
also some other toxicity biomarkers could be studied from
their sera.
Group Two: Although a group of 68 randomly selected
persons comprising 47 males and 21 females (Group II) from
the same village agreed to donate urine and blood samples,
they refused to sign ‘informed consent’ unless they were
assured that they would receive the actual drug and not any
‘placebo’. This was understandable, since many of them
were indeed very sick, suffering from serious liver and lung
ailments, and bad skin lesions in the case of a few. Our earlier
results on randomized placebo-controlled animal experiments
clearly showed that the potentized homeopathic remedy
Arsenicum Album-30 ameliorated As toxicity as revealed
from various protocols (10–16). On humanitarian and ethical
grounds of trying to alleviate their suffering (there are no hos-
pitals or medical clinics nearby this village to render any emer-
gency service to the subjects, if necessary), we agreed to give
these subjects (Group II) only ‘verum’, twice daily for 10 con-
secutive days, each dose containing eight small globules
(No. 20) soaked with the medicine and then the remedy was
withdrawn for 15 days. Thereafter, the cycle was repeated
twice in the same manner. Subsequently, the drug was admin-
istered only for seven consecutive days, keeping always a gap
of 15 days in between.
The volunteers of both Groups I and II were advised to take
As-free water (from a plant nearby, water from which meas-
ured <10 ppb of As at periodical surveys) to the maximum
possible extent during the course of the experiment, although
they had actually been drinking water mostly from this plant
ever since its installation. This was necessary because these
people occasionally drink water from shallow tube wells con-
taminated with As after they exhausted the As-free drinking
water they carried with them to the fields.
Choice of Technique for As Determination
In our initial trials for standardization of As determination in
water, urine and blood, we used (i) acid undigested samples;
(ii) partially digested samples by treating with a single acid
solution; and (iii) fully digested samples with three acids
(see below), taken in containers for digestion like (i) glass
beakers followed by transfer to volumetric flasks before
recording data in AAS; and (ii) directly in volumetric flasks
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Serial
number
Age Sex Symptoms
Skin symptom Digestive problem (indigestion,
stomach ache, lack of appetite,
pain in liver region, etc.)
Others, if any
BD AD-12 days BD AD-12 days BD AD-12 days
Group I
15 0 M þþ þþ þ Appetite improved Dizziness Improved
22 7 M þþ þ Appetite improved Cold and cough Improved
3 23 F Nil Nil þ Appetite improved,
digestion better
Dizziness, weakness,
burning of eyes
Overall improvement
of all symptoms
4 7 F Nil Nil Nil Nil Nil Nil
5 13 M Nil Nil Nil Nil Dizziness, nausea Much better
6 10 M Nil Nil þ Appetite improved Reeling, dizziness Considerably reduced
7 8 F Nil Nil þ Improved Weakness Reduced
8 37 M Nil Nil þ Appetite slightly improved Burning of eyes Reduced considerably
9 35 F Nil Nil þ Digestive ability improved,
increased appetite
Headache, high blood
pressure, tachycardia,
burning of eyes
Overall improvement
of all symptoms
10 55 F Nil Nil þ Improved appetite Abdominal pain Decreased
11 27 M þþ þ Improved Headache Less frequent
12 8 F Nil Nil þ Appetite improved Nil Nil
13 27 M Nil Nil þ Appetite improved Nil Nil
14 27 M þþ þþ þ Much better Headache Reduced in frequency
15 7 M Nil Nil þ Better Abdominal pain Improved and less frequent
16 11 M Nil Nil þ Better digestive ability,
increased appetite
Burning of eyes, occasional
leg muscle cramp
Overall improvement
17 7 M Nil Nil þ Appetite improved, less
stomach ache
Hearing impairment Not improved
18 50 M þþþþ þþþþ þ Appetite improved,
less pain in liver region
High blood pressure,
dizziness, prostate problem
Minor improvement
19 50 M Nil Nil þ Appetite improved Nil Nil
20 20 M Nil Nil Nil Nil Nil Nil
21 35 F Nil Nil Nil Nil Headache, vision problem,
chest pain, cough
General improvement
22 8 F Nil Nil þ Appetite improved Nil Nil
23 33 M Nil Nil þ Improved appetite Cough and cold Improved
24 13 F Nil Nil þ Improved appetite,
less pain in liver region
Nil Nil
25 42 F þþ þþ Nil Nil Thyroid problem, high blood
sugar, pain in leg, muscle,
waist and thigh
Improvement in muscle pain
26 15 M Nil Nil Nil Nil Nil Nil
27 33 M Nil Nil þ Appetite improved,
less pain in liver region
Headache, weakness,
palpable liver enlargement,
shivering of body
Slight improvement of liver
size
28 17 M Nil Nil Nil Nil Weakness Improved
29 40 F þþ þþ þ No palpable change Nil Nil
30 28 F Nil Nil Nil Nil Cardiac problem No palpable change
31 49 M Nil Nil þ Improved appetite Chest pain Slight relief
32 23 M Nil Nil Nil Nil Nil Nil
33 50 M þþþ þþþ þ Improved appetite Cough and cold A little relief
34 40 F þþþ þþþ þ Less pain in liver region Nil Nil
35 70 M þþ þþ þ Improved appetite Cough and cold A little relief
36 30 M þþþ þþþ þ Less stomach ache, improved
appetite
Nil Nil
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Serial
number
Age Sex Symptoms
Skin symptom Digestive problem (indigestion,
stomach ache, lack of appetite,
pain in liver region, etc.)
Others, if any
BD AD-12 days BD AD-12 days BD AD-12 days
37 39 F þþ þþ Nil Nil Cough and cold A little relief
38 49 M þþ þþ Nil Nil Cough and cold A little relief
39 49 M þþþþ þþþ Nil Nil Nil Nil
40 43 M þþ þþ þ No palpable change Nil Nil
41 38 F Nil Nil þ Relief of pain in stomach,
improved appetite
Cardiac problem,
asthma, cough and cold
A little relief from asthma
42 36 M þþ Nil Nil Cough and cold No palpable change
43 25 F þþþþ þþþ Nil Nil Swollen legs Some decrease in swelling
44 49 M þþ þþ þþ No palpable change Cough and cold A little relief
45 49 F þþ þ A little decrease in stomach
ache
Cardiac problem,
asthma, high BP
Some relief from asthma
46 23 F þþ þþ þ Improved appetite Nil Nil
47 13 M Nil Nil þþ Stomach ache less frequent Nil Nil
48 12 F Nil Nil þ Improved appetite Nil Nil
49 28 F þþ þþ þþ No palpable change Cough and cold, headache Some relief
50 53 M þþþ þþ þþ Stomach ache less, improved
appetite
Cardiac problem,
cough and cold
Some relief from cough
51 10 M Nil Nil Nil Nil Cough and cold A little relief
52 24 M þþ þþ þþ Improved appetite Dizziness A little better
53 40 F þþþ þþþ þþ Pain in liver region less
frequent, Improved appetite
Cough and cold, headache,
high blood sugar
Overall improvement
BD AD-3M BD AD-3M BD AD-3M
Group II
1 25 M Nil Nil Nil Nil Nil Nil
2 22 M Nil Nil Nil Nil Nil Nil
3 14 F Nil Nil Nil Nil Nil Nil
42 5 M þþþþ þþþ þ Improved appetite Cough and cold A little better
53 7 M þþþ þþ þ Less pain in liver region,
improved appetite
Cough and cold A little better
6 28 M Nil Nil Nil Nil Nil Nil
74 5 Fþþ þþ þ Improved appetite Swelling of hands and feet Some decrease in swelling
8 30 M Nil Nil þ Increased digestive ability,
stomach ache less frequent
Nil Nil
91 3 M þþ þþ þ Improved appetite Nil Nil
10 25 F þþ þ Stomach ache less,
improved appetite
Cough and cold A little better
11 30 M þþ þþ þ Improved appetite Nil Nil
12 35 M þþ þþ þ Relief of pain in stomach,
improved appetite
Headache Some relief
13 30 M Nil Nil Nil Nil Headache, dizziness A little better
14 12 M þþ þþ þ Improved appetite Cough and cold A little better
15 34 M Nil Nil Nil Nil Nil Nil
16 19 M Nil Nil Nil Nil Nil Nil
17 12 M þþ þ Stomach ache less frequent Headache Some relief
18 25 F þþ þ Improved appetite Cough and cold A little better
19 28 M Nil Nil Nil Nil Nil Nil
20 15 M þþ þ þ Improved appetite Headache Some relief
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Serial
number
Age Sex Symptoms
Skin symptom Digestive problem (indigestion,
stomach ache, lack of appetite,
pain in liver region, etc.)
Others, if any
BD AD-3M BD AD-3M BD AD-3M
21 34 M þþ þ Pain in liver region less
frequent, improved appetite
Nil Nil
22 45 F þþ Nil Nil Nil Nil
23 40 M þþ þ þ Stomach ache less frequent,
improved appetite
Nil Nil
24 50 M þþ þ Pain in liver region less
frequent, improved appetite
Nil Nil
25 35 F þþ þ Better digestive ability,
increased appetite
Diabetic Decreased blood sugar
26 45 M þþ þ þ Improved appetite Nil Nil
27 25 F þþ þ þ Improved appetite Nil Nil
28 30 M þþ þ Relief of pain in stomach,
improved appetite
Nil Nil
29 42 M þþ þþ Nil Nil Nil Nil
30 30 M þþ þþ þ Improved appetite Headache Some relief
31 26 F þþ Nil Nil Nil Nil
32 12 M þþ þ þ Better digestive ability,
increased appetite
Nil Nil
33 40 F Nil Nil þ Improved appetite Nil Nil
34 42 M Nil Nil Nil Nil Nil Nil
35 35 F Nil Nil þ Stomach ache less frequent,
Improved appetite
Cough, dizziness A little better
36 8 M Nil Nil Nil Nil Nil Nil
37 12 M Nil Nil þ Improved appetite Nil Nil
38 27 F þþ þ Appetite improved, less pain
in liver region
Nil Nil
39 10 M Nil Nil þ Stomach ache less frequent,
improved appetite
Cough and cold A little better
40 42 M Nil Nil þ Improved appetite Nil Nil
41 40 M Nil Nil þ Pain in liver region less
frequent, improved appetite
Nil Nil
42 38 M Nil Nil Nil Nil Cough and cold A little relief
43 17 M þþ þ Better digestive ability,
increased appetite
Cough and cold A little better
44 25 M Nil Nil þ Relief of pain in stomach,
improved appetite
Nil Nil
45 44 M þþ þ Improved appetite Cough and cold A little better
46 36 M Nil Nil þ Better digestive ability,
increased appetite
Cough and cold A little relief
47 44 M Nil Nil þ Pain in liver region less
frequent, Improved appetite
Nil Nil
48 35 M þþþþ þþþ þ Improved appetite Nil Nil
49 27 F Nil Nil þ Stomach ache less frequent Nil Nil
50 13 M Nil Nil Nil Nil Nil Nil
51 40 F þþ þ Improved appetite Headache, reeling A little better
52 20 F Nil Nil Nil Nil Nil Nil
53 20 F þþ Nil Nil Nil Nil
54 22 M Nil Nil Nil Nil Nil Nil
55 8 F þþ þ Better digestive ability,
increased appetite
Nil Nil
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were more concerned with the inorganic (more toxic) than
the organic As, we found the following method to be quite reli-
able producing consistent results. This was possibly due to less
matrix effect, which tended to give erratic results at times with
the other techniques.
Analytical Methods for Estimation of As in
Urine and Blood Samples
Sample Collection
Water: Samples of drinking water from the As-free water plant
and the 10 tube wells that were being used as a source of
water for all domestic purposes, including cooking of food,
were periodically brought to the laboratory to test their
As content.
Urine and blood: First void urine samples were collected
from all volunteers in separate sterilized preacid washed
bottles. Blood samples were taken from the vein using a dis-
posable hypodermic needle and transferred into two blood-
collecting vials—one containing EDTA for As analysis and
the other without EDTA for serum analysis. Immediately after
collection, the urine and a part of the blood samples were
stored at  20 C until further processing for As estimation in
the laboratory.
Preparation of the Samples for As Analysis
Water samples were tested either by adding (i) only HNO3
(commonly done) or (ii) by adding a mixture of HNO3,
HClO4 and H2SO4 like that of urine and blood samples. Since
there was negligible difference in As content shown by these
two methods, we preferred to continue with the same method
of triple acid treatment for all three samples.
One milliliter of each of the water, urine and blood samples
was taken separately into 25 ml volumetric flask, to which
5.0 ml of a mixture of extra pure acids (HNO3/HClO4/H2SO4
3:1:1) was added and kept for predigestion for  2h .
Subsequently, the flasks were heated to 170–180 Co na
temperature-controlled hot sand bath. The digestion continued
(for  5.0 h) until a colorless liquid (of  1.0 ml) was obtained.
After digestion, the flask with the content was cooled down
overnight at room temperature. Further, to the content in
the flask, 1.0 ml of concentrated HCl (supra pure grade)
and 1.0 ml of potassium iodide (KI) solution (5.0 g l
 1) were
added with requisite amount of double distilled water to
make the volume up to 25 ml so as to get  200 mg l
 1 KI
in the final solution to be aspirated in the hydride
generator. The hydride (arsine) was generated by continuous
mixing of the sample with a solution of sodium borohydride
(1.0%, w/v) and HCl (4.0 M). Arsenic content in the
solution was determined with the help of a hydride
generation atomic absorption spectrophotometer (AAS) at
wavelength 193.7 nm and lamp current 8.0 mA [made up of
GBC (Australia), model Avanta; equipped with a HG 3000
system]. All analyses were performed in triplicate including
the blank. All chemicals used were of analytical grade. Stand-
ard As solution procured from E. Merck, Germany, was
used as the standard for AAS calibration to detect As in all
human samples.
Table 1. Continued
Serial
number
Age Sex Symptoms
Skin symptom Digestive problem (indigestion,
stomach ache, lack of appetite,
pain in liver region, etc.)
Others, if any
BD AD-3M BD AD-3M BD AD-3M
56 50 F Nil Nil Nil Nil Nil Nil
57 15 M Nil Nil Nil Nil Nil Nil
58 60 F þþ þ þ Improved appetite Headache breathlessness Some relief
59 13 M þþ þ Better digestive ability,
increased appetite
Headache Some relief
60 14 M þþ Nil Nil Headache, dizziness A little better
61 46 M þþ þ Improved appetite,
less pain in liver region
Weakness, headache,
reeling, high BP
General improvement
62 42 M þþ þ Less frequent stomach
ache, improved appetite
Insomnia, headache Some relief
63 7 F þþ Nil Nil Nil Nil
64 35 M þþþ þþ Nil Nil Nil Nil
65 23 F Nil Nil Nil Nil Nil Nil
66 4 M Nil Nil Nil Nil Nil Nil
67 24 F Nil Nil Nil Nil Nil Nil
68 16 M þþ þ Nil Nil Nil Nil
BD, before drug; AD, after drug; M, month.
One ‘þ’ sign denotes one arbitrary unit of expression of disease state.
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Other Biomarkers
Preparation of Blood Samples
Blood samples were kept for 5–6 h at 37 C in the laboratory
for isolation of serum. Serum was centrifuged at 10000 g for
30 min and 0.2 ml of supernatant (serum) was taken and
diluted with 19.8 ml of phosphate-buffer saline.
All standard protocols for quantitative estimation of the
enzymes were followed: e.g. Walter and Schutt (19) for AcP
and AlkP, Bergmeyer and Brent (20) for AST and ALT, Buege
andAust(21)forLPOandEllman(22)forGSHwerefollowed.
Dose of Medicine Orally Administered
Eight small globules of pharmaceutical grade sugar (No. 20)
soaked with Arsenicum Album-30 [Schwabbe German/Boiron
Laboratories, Lyon, France, were prepared by following
the homeopathic principle of dilution and succussion (see
ref. (16) for detailed procedure of drug preparation)] to be
taken twice daily half an hour before or after taking any food
or beverage. Following homeopathic restrictions, patients
were barred from taking raw onion or garlic during the period
of the study.
Statistical Analysis
The SDs and errors were determined and the significance
levels were calculated between the data of each parameter of
study obtained before and after administration of the remedy
for the specified periods of time by the Student’s t-test.
Results
Changes in As Content
The mean As content of drinking water from the As-free
plant was <10 ppb, but the As contents of 10 tube wells
providing water for other purposes varied from an average of
65.9–330.37 ppb from one tube well to the other.
Group One: Results of Group I (Fig. 1) showed that there
was a fluctuation of As concentration in the urine of
both ‘placebo’ and ‘verum’ fed subjects on a day-to-day basis
but the concentration in the latter group was always higher
compared with that in the former. The differences in the
concentration between the two groups (drug versus placebo)
were generally a little higher during the first week, but
subsequently the differences were not so palpable, particularly
at the 11th day. But from this study, it was quite evident
that the efficacy of the ‘verum’ in the mobilization of As was
always greater than that of the ‘placebo’ during all 11 days.
Group Two: The mean As content in urine and blood (Fig. 2a
and b) of the patients (Group II) before administration of the
drug was higher (being 43.75 ppb in urine and 24.13 ppb in
blood) than the normal permissible range (3.33–25.55 ppb
and 0.3–2.0 ppb, respectively) (23–28). The content in urine
at 7th day after administration of the drug was found to rise
up to a strikingly high level (62.30 ppb), but thereafter it stead-
ily declined to reach almost the lower limit of normal range
by 45th day (10.78 ppb) (Fig. 2a). Regarding the As content
in the blood (Fig. 2B), a significant decline was recorded on
the 30th day, returning to normal range on the 60th day after
drug administration. Since the first estimation was taken only
after 30 days, we do not know if it also increased like that in
the urine at any point during the intervening period. A trig-
gered release of As into urine on medication and its subsequent
elimination from the body probably sets a new As equilibrium
the blood that was eventually manifested later by a low As con-
centration in the blood.
Changes in Toxicity Biomarkers
Interestingly the activities of all toxicity denoting enzymes in
blood, viz., AST, ALT, AcP and AlkP showed a steady decline
and attained almost normal levels by 2 months time after drug
administration (Fig. 3a–d). Concomitantly, the LPO activity
also decreased with an increase in the GSH levels in the sub-
jects (Fig. 3e and f). Extensive toxicological studies have
now established that increase in LPO, AlkP and AcP activities
along with a decrease in GSH levels denote cytotoxicity
and hepatocellular dysfunctions associated with As toxicity
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Figure 1. Arsenic (As) content in urine of verum fed subjects vs. placebo fed axes for 11 consecutive days. *P < 0.05, **P < 0.01.
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correlations between As concentration in blood and urine and
the activities of these enzymes (negative with GSH, and posit-
ive with AST, ALT, AcP, AlkP and LPO). A desirable change
in these biomarkers (an increase in GSH and decreases in ALT,
AST, AcP, AlkP and LPO) on drug administration suggests its
potential in alleviating As toxicity in humans.
Any Preference of the Remedy According to As Load
or Sex?
Pending a more critical analysis of the data on changes in As
content in urine and blood and favorable changes in the activ-
ities of the enzymes, it was impossible to determine without
further study if the drug was more effective in those with
higher or medium loads of As in the body than those with
lower levels. It was, however, clear that sex did not influence
the efficacy. The drug was able to bring about statistically sig-
nificant changes in the enzyme activities of both the urine and
the blood As (Figs. 1, 2a and b).
Improvements in other Aspects of Health
Indeed, along with the changes in these parameters, the drug
administration also improved considerably the overall physical
strength, appetite and food digestion, and also mental cheerful-
ness in these subjects with a general feeling of better health.
Even within 2 months, some volunteers with severe skin
complaints started showing some amelioration of their symp-
toms (Fig. 4a–d).
Discussion
The results on various toxicity biomarkers obtained in the
present study were apparently consistent with the reduction
of As content observed in the different samples after the
specified periods of drug administration. Our approach was
holistic: by comparing the data of the pre-drug administration
levels at different fixation times we sought to understand if
the remedy was causing any positive modulations that indic-
ated better health conditions in the subjects. This was done
primarily to know if the administration of the remedy showed
any positive modulations indicative of better health conditions
of the subject.
Free radicals are electrophilic species that can react with
cellular components. The process of LPO is initiated by the
attack of a free radical, that could be emanated by As (32),
on unsaturated lipids and the resulting chain reaction is ter-
minated by the production of lipid breakdown products, lipid,
alcohols, aldehydes and malonaldehyde. There is a cascade
of peroxidative reaction in hepatotoxicity, which has been a
common symptom of As victims. This ultimately leads to the
destruction of lipid and thus the liberation and quantification
of malonaldehyde reflects the state of hepatotoxicity. An
increased level of LPO, therefore, may affect membrane struc-
ture by altering fluidity of the membrane. Interestingly, the
enhanced activity of LPO observed in the baseline data has
been considerably reduced following administration of the
potentized homeopathic drug, which is a significant finding.
Phosphatases are enzymes that catalyze the splitting off of
phosphoric acids from certain monophosphoric esters, a reac-
tion of considerable importance in several body processes
including neoplastic growth. AcPs and AlkPs have been dir-
ectly implicated in the extent of cellular damage and toxicity
(33–35), particularly of liver and cardiac tissue. The primary
importance of measuring AlkPs is to check the possibility
of mainly liver diseases (ALP-1) or bone diseases (ALP-2),
which are prevalent in As victims. The level increases mainly
as a result of liver, bile duct or gall bladder dysfunction,
particularly in adults. The study of AlkP levels becomes
significant in effectively denoting the alteration of toxicity
levels during the period of drug administration. Similarly,
the activities of enzymes like ALT/GPT (Glutamate pyruvate
aminotransferase) and AST/GOT (Glutamate oxaloacetate
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544 Can homeopathic remedy combat arsenic poisoning in humanaminotransferase) are found in hepatocytes and striated (skel-
etal and cardiac) muscle cells and increased serum ALT/AST
activity has been reported in hepatocellular injury or necrosis
of striated muscle (36,37). Determination of ALT activity is
a relatively sensitive indicator of hepatic damage and release
of ALT from the cytosol can occur secondary to cellular nec-
rosis or as a result of cellular injury with membrane damage
and bleb formation (38). Thus, the changes in activity and con-
centration of marker enzymes like AcP, AlkP, ALT and AST
in blood sera could reflect the state of hepatotoxicity (35).
Reduced GSH, a tripeptide containing cysteine, is an import-
ant thiol compound present in cells. It plays an crucial role in
regulation of cellular proliferation and cellular defense. It has
a nucleophilic thiol group and it can modify substances in
one of three ways: (i) by chemical reaction with a reactive
metabolite to form a conjugate; (ii) by donation of a proton
or hydrogen atom to reactive metabolites or free radicals; or
(iii) by conjugation catalyzed by a GSH transferase or else
other metabolites may chemically oxidize to GSGG from
GSH (34). Therefore, exposure of cells to As leads to GSH
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eCAM 2005;2(4) 545depletion. Positive alteration in endogenous GSH is
encountered in the present investigation after the administra-
tion of the homeopathic remedy, which conforms with the
activities of the other biomarkers.
Thus, the notable changes observed in activities of these
enzymes/biomarkers could be considered as convincing indic-
ators of improvement in hepatic functions, which in turn were
amply reflected in increased appetite reported by most of the
subjects taking the ‘verum’ and also as factors influencing
the amelioration of other As-induced toxicity.
The present study was essentially a sequel to our earlier
randomized placebo-controlled studies (10–16), which had
convinced us of the efficacy of the potentized homeopathic
remedy, Arsenicum Album-30, to ameliorate As-induced
genotoxicity and cytotoxicity in mice (a mammalian model
quite close to humans) through the use of several widely
accepted cytogenetical and biochemical protocols. Although
it would have been preferable to conduct the entire study
with a ‘double-blind placebo-controlled’ protocol to establish
the clinical efficacy of this homeopathic remedy on a sounder
scientific footing, the positive results obtained in the subjects
taking the ‘verum’ were highly encouraging. They indicated
the great potential of the remedy for large-scale use to
ameliorate the toxicity induced by chronic intake of
groundwater As in millions of poor rural people living in
remote places. Even some subjects with bad skin symptoms
also started showing signs of improvement. Therefore, this
study should provide a stimulus for other researchers to take
up further randomized placebo-controlled trials. However,
conducting experiments on As victims in As contaminated
villages have some inherent limitations since many of the As
victims are very sick and suffer from severe depression. To
motivate the poor and illiterate villagers to subject themselves
to a placebo-controlled study is much more difficult than can
be imagined. Furthermore, there is always a risk that a
patient’s condition will abruptly deteriorate during a placebo-
controlled study without the availability of any adequate meas-
ures to save his or her life. For this reason, most drug trials
made so far by others have only been conducted in either clin-
ics or hospitals. In fact, during our study, a young girl in a crit-
ical stage approached us for treatment and was refused in view
of her serious condition and was advised for immediate
hospitalization; she died only a couple of days later. Had she
been included in our study and received a placebo on a ran-
domized basis, a deep sense of sadness and moral responsibil-
ity would have plagued the researchers since they would have
deprived her of medicine or palliative care during her last few
days. Further, monitoring regular uptake of medicine/placebo
(a) (b)
(c) (d)
Figure 4. (a–d) Typical skin symptom on palms (upper row) and soles (lower row) of a victim before (left) and 2 months (right) after administration of Arsenicum
Album-30.
546 Can homeopathic remedy combat arsenic poisoning in humanby a large number of subjects in remote As contaminated
villages is also an area of concern. Bringing materials (e.g.
blood samples) regularly from distant As villages to the
laboratory for analysis within a reasonable time frame is
another area of difficulty. Despite all these limitations, the
initial results indicated in a reasonably convincing way the
efficacy of the homeopathic remedy by Arsenicum Album-30
in bringing back the spirit and energy of most As victims,
who showed distinct benefits and improvement in their
health conditions after administration of the remedy for
3 months.
How the ultralow dose of the drug could bring forth such
favorable changes in respect to alleviating As concentration
in urine and blood samples and showing positive modulations
with respect to different toxicity biomarkers in sera of human
volunteers exposed to groundwater As remains unclear. All
enzymatic regulations are strictly under genetic control, one
possible explanation could be that this ultrahigh diluted
drug, on oral administration, must have produced signals
through specific receptors to trigger/deactivate some relevant
and specific genes (39,40) that could bring forth positive
modulations of various parameters in optimizing different
functions.
More experiments (preferably double-blind placebo-
controlled trials) with larger groups of affected people from
adjoining areas is essential before recommending large-scale
use of this potentized drug on As affected people. More trials
are necessary to examine how long this potency (Arsenicum
Album-30) can continue to work effectively (after these initial
3 months) and whether more optimum dose(s)/potency(ies)
can yield better and sustainable results. It would also be inter-
esting to know if the duration of intake of the drug on a regular
basis can be minimized with the use of a higher potency of the
drug (for example, Arsenicum Album-200). At least, poor peo-
ple inhabiting As-risk areas of the third world countries where
provision for safe As-free drinking water has not yet been
made or no suitable medical help is available due to the remo-
teness of the area or any other more efficient drug is made
available to them, may be benefited for sometime by taking
the drug. But a note of caution: for a sustainable relief from
As poisoning, the need for taking ‘As-free’ drinking water is
extremely important and essential, because if As continues to
enter, it is simply not possible to maintain outward mobiliza-
tion of the entire amount for long through the use of any
drug alone. Further, the use of some intercurrent ‘constitu-
tional’ or ‘symptomatic’ homeopathic remedies may also be
necessary depending on the degree of damage already done
to different organs through chronic toxicity of this compound,
expressing thereby some more specific symptoms. Therefore,
a close monitoring of the victims periodically under the super-
vision of a qualified homeopathic practitioner should be highly
encouraged. Further works in these directions are in progress
and some other biomarkers are also being considered. We
would encourage other groups to conduct similar trials to test
the efficacy of the drug and confirm or refute the findings of
our pilot study.
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